Bringing the Oncology Community Together

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

G. Thomas Budd, MD
Published Online: Tuesday, June 25, 2013
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses the background and results of the S0221 trial in breast cancer.

Previously, Budd says, researchers analyzed two dose-dense regimens and found that treatment with doxorubicin-cyclophosphamide followed by paclitaxel given every two weeks was more effective than the same regimen with all drugs given every three weeks.

Another trial looked at the same regimen given weekly and compared it to treatment every three weeks. In this analysis, weekly treatment was better than treatment every three weeks.

In the S0221 trial, researchers compared these two schools of thought, Budd says. The trial showed that in terms of efficacy, these two regimens produced similar outcomes, but the side effects differed.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Related Articles
Experts Debate Utility of Genomic Profiling in Daily Practice
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.